Suzhou Degen Biopharmaceutical Co., Ltd, a leading specialist in PROteolysis TArgeting Chimeras (PROTAC) technology in China, has announced that its oral dual-targeted PROTAC drug, DG01, has been granted approval by the National Medical Products Administration (NMPA) to proceed with clinical studies for advanced or metastatic castration-resistant prostate cancer and liver cancer, along with other solid tumor types.
DG01 is a low molecular weight PROTAC drug with a dual degradation mechanism, capable of simultaneously degrading GSPT1 and SRD5A3 target proteins. This innovative approach induces the downregulation of androgen receptor (AR) and its splice variant AR-V7, effectively inhibiting the proliferation of prostate cancer cells. Preclinical studies have demonstrated DG01’s significant inhibitory effect on tumor growth in prostate cancer cell lines, positioning it as a potential therapeutic agent for the treatment of prostate cancer.- Flcube.com
